SciClone Pharmaceuticals Inc (NASDAQ:SCLN)

9.36
Delayed Data
As of Jul 28
 -0.19 / -1.99%
Today’s Change
4.74
Today|||52-Week Range
11.71
+6.85%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$473.7M

Company Description

SciClone Pharmaceuticals, Inc. is a specialty pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. The company operates its business through two segments: China and Rest of the World including United States. Its ZADAXIN product is approved in over 30 countries and used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers. SciClone Pharmaceuticals was founded in 1990 and is headquartered in Foster City, CA.

Contact Information

SciClone Pharmaceuticals, Inc.
950 Tower Lane
Foster City California 94404-2125
P:(650) 358-3456
Investor Relations:
(650) 358-1447

Employees

Shareholders

Other institutional39.60%
Mutual fund holders36.36%
Individual stakeholders16.02%

Top Executives

Friedhelm BlobelPresident, Chief Executive Officer & Director
Wai-Shun Wilson CheungChief Financial Officer & Senior Vice President
Charles MengVice President-Compliance & General Counsel
Robert S. KingVice President-Product Development & Manufacturing
Lan XieChief Financial Officer-China Operations

To view my watchlist

Not a member yet?

Sign up now for a free account